Pearls and pitfalls of ChatGPT in medical oncology
Vivek Subbiah
JCO Precision Oncology
Targeting All BRAF Alterations: The (Re)-Search Continues
Cell Reports Medicine
Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers
Clinical Cancer Research
The Landscape of Alterations from 1407 Ultra-Rare Sarcomas from the AACR GENIE Database: Clinical Implications
ESMO Open
Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study
Cancer Research
RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond
Cancer
TRKing sarcomas for precision medicine: Seek, and ye shall find!
Cell Reports Medicine
Clinical development and management of adverse events associated with FGFR inhibitors
JCO Precision Oncology
Exceptional Responses to Selpercatinib in RET Fusion-Driven Metastatic Pancreatic Cancer
Cancer Discovery
RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations